ClinicalTrials.gg
RecruitingNCT07168122Updated Nov 20, 2026

Establishment and Clinical Application of Reference Intervals of Salivary Cortisol

An observational study in Healthy Adult, Cushing Syndrome and Adrenal Insufficiency, sponsored by Shanghai 6th People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Shanghai 6th People's Hospital · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 20, 2026Start date movedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
220
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The goal of this observational study is to establish the normal reference intervals of salivary cortisol and optimal cut-offs for Cushing's sydrome and adrenal insufficiency.

Read the detailed description

Saliva testing is a non-invasive alternative to blood tests for measuring cortisol, a key hormone for assessing endocrine status and diagnosing conditions like Cushing's syndrome. It accurately reflects physiologically active free cortisol. However, its clinical use is hampered by extremely low cortisol concentrations and the lack of reliable detection methods. We have developed two advanced technologies: an immunomagnetic-bead-based LC-MS assay with simplified preparation, and a fluorescence immunoassay system for point-of-care testing. To promote their clinical adoption, this study will establish normal reference intervals of salivary cortisol for both methods in a healthy population and optimal cut-offs in cases of Cushing's sydrome and adrenal insufficiency.

02

Conditions studied

  • Healthy Adult
  • Cushing Syndrome
  • Adrenal Insufficiency
03

In context

Cushing Syndrome

123 studies on the registry are indexed under Cushing Syndrome; 42 are open to participants now.

This study's planned enrollment of 220 is above the median of 121 across 63 observational studies indexed under Cushing Syndrome.

Browse Cushing Syndrome studies →

Lead sponsor

Shanghai 6th People's Hospital is the lead sponsor of 70 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The participants are enrolled from Shanghai Sixth People's Hospital, Shanghai.

Eligibility criteria

Healthy Volunteers:

Inclusion Criteria:

  1. Age ≥ 18 and ≤ 60 years old;
  2. (BMI) ≥ 18.5 and ≤ 24.9 kg*m\^-2;
  3. No previous history of chronic diseases such as hyperglycemia, hypertension, dyslipidemia, coronary heart disease and stroke;
  4. Normal glucose regulation, defined as: fasting blood-glucose \< 5.6 mmol/L, 2-hour blood-glucose after glucose load \< 7.8 mmol/L, and (HbA1c) \< 5.7%.

Exclusion Criteria:

  1. Liver or kidney dysfunction, (ALT) or aspartate aminotransferase (AST) or direct higher than 1.5 times the , or serum creatinine >115 μmol/L;
  2. Pregnancy or lactation women, or people with cancer or mental illness;
  3. Factors affecting cortisol levels, including hypothalamus-pituitary-adrenal axis disease, disease (systemic lupus erythematosus, rheumatoid arthritis, etc.), diagnosed mental disease, Alzheimer's disease, alcoholism (alcohol > 60 g/d for male, >40 g/d for women) and therapy in the past 3 months (females with or estrogen);
  4. Factors affecting saliva collection, such as serious oral problems (oral ulcers, gingival bleeding);
  5. Night shift workers, who are awake from 11:00 PM to 7:00 AM;
  6. Acute infection (body temperature ≥ 37.3 ℃ or C-reactive protein > 50 mg/L).

Cases:

Inclusion Criteria:

  1. Aged 18 to 80 years old;
  2. Patients with suspected Cushing's syndrome or adrenal insufficiency.

Exclusion Criteria:

  1. Corticosteroid therapy within the last 6 weeks;
  2. Acute infection;
  3. Severe oral conditions;
  4. Severe liver and kidney dysfunction;
  5. Alcoholism, depression, or other psychiatric disorders.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
220 participants (estimated)
Patient registry
No

Groups and cohorts

  • Heathy Volunteers

    120 Healthy Volunteers for the establishment of reference intervals of salivary cortisol

  • Cushing's sydrome

    50 cases diagnosed with Cushing's sydrome

  • Adrenal insufficiency

    50 cases diagnosed with adrenal insufficiency

06

What researchers measure

Primary outcomes

  1. Reference intervals of salivary cortisol

    Salivary cortisol levels were evaluated by immunomagnetic-bead-based LC-MS assay and fluorescence immunoassay system to establish its reference intervals according to the 2.5th and 97.5th percentiles.

    Time frame: 8:00 on the day of sample collection

  2. Optimal cut-off and diagnostic accuracy of salivary cortisol in Cushing's syndrome

    The diagnostic cut-off for each analysis method was defined as either the calculated upper reference interval (97.5th percentile) or the optimal value determined by the Youden index. The sensitivity, specificity and area under curve for Cushing's syndrome was calculated using samples from all available healthy controls and cases.

    Time frame: 8:00 on the day of sample collection

  3. Optimal cut-off and diagnostic accuracy of salivary cortisol in adrenal insufficiency

    The diagnostic cut-off for each analysis method was defined as either the calculated lower reference intervals (2.5th percentile) or the optimal value determined by the Youden index. The sensitivity, specificity and area under curve for adrenal insufficiency was calculated using samples from all available healthy controls and cases.

    Time frame: 8:00 on the day of sample collection

Secondary outcomes

  1. Agreement in assessment of salivary cortisol

    To assess the agreement in assessment of salivary cortisol between immunomagnetic-bead-based LC-MS assay and fluorescence immunoassay system

    Time frame: 8:00 on the day of sample collection

  2. Between-groups differences in salivary cortisol of healthy volunteers with different age ranges

    Comparsion of salivary cortisol levels in subgroups of age

    Time frame: 8:00 on the day of sample collection

  3. Between-groups differences in salivary cortisol of healthy volunteers with different sex

    Comparsion of salivary cortisol levels in subgroups of sex

    Time frame: 8:00 on the day of sample collection

  4. Between-groups differences in salivary cortisol of healthy volunteers with different body mass index ranges

    Comparsion of salivary cortisol levels in subgroups of body mass index

    Time frame: 8:00 on the day of sample collection

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2026 (actual). Primary completion is estimated for Jun 2027, 17 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Sep 2025 → Jan 2026, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 11, 2025
StartActual
Jan 1, 2026was Sep 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2025→Jan 1, 2026 (actual)
Nov 20, 2026
Primary outcomes
2 time frame changed, 1 removed
What changed in the outcomes
  • RemovedComparison of diagnostic accuracy of salivary cortisol in Cushing's syndrome and adrenal insufficiencyTime frame: 8:00 or 23:00 on the day of sample collection
  • Time frameReference intervals of salivary cortisol8:00, 16:00 and 23:00 on the day of sample collection → 8:00 on the day of sample collection
  • Time frameOptimal cut-off and diagnostic accuracy of salivary cortisol in Cushing's syndrome23:00 on the day of sample collection → 8:00 on the day of sample collection
Nov 20, 2026
Secondary outcomes
4 time frame changed
What changed in the outcomes
  • Time frameAgreement in assessment of salivary cortisol8:00, 16:00 and 23:00 on the day of sample collection → 8:00 on the day of sample collection
  • Time frameBetween-groups differences in salivary cortisol of healthy volunteers with different age ranges8:00, 16:00 and 23:00 on the day of sample collection → 8:00 on the day of sample collection
  • Time frameBetween-groups differences in salivary cortisol of healthy volunteers with different sex8:00, 16:00 and 23:00 on the day of sample collection → 8:00 on the day of sample collection
  • Time frameBetween-groups differences in salivary cortisol of healthy volunteers with different body mass index ranges8:00, 16:00 and 23:00 on the day of sample collection → 8:00 on the day of sample collection
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Start date Sep 1, 2025→Jan 1, 2026 (now actual)
    Primary outcomes 2 time frame changed, 1 removed
    What changed in the outcomes
    • RemovedComparison of diagnostic accuracy of salivary cortisol in Cushing's syndrome and adrenal insufficiencyTime frame: 8:00 or 23:00 on the day of sample collection
    • Time frameReference intervals of salivary cortisol8:00, 16:00 and 23:00 on the day of sample collection → 8:00 on the day of sample collection
    • Time frameOptimal cut-off and diagnostic accuracy of salivary cortisol in Cushing's syndrome23:00 on the day of sample collection → 8:00 on the day of sample collection
    Secondary outcomes 4 time frame changed
    What changed in the outcomes
    • Time frameAgreement in assessment of salivary cortisol8:00, 16:00 and 23:00 on the day of sample collection → 8:00 on the day of sample collection
    • Time frameBetween-groups differences in salivary cortisol of healthy volunteers with different age ranges8:00, 16:00 and 23:00 on the day of sample collection → 8:00 on the day of sample collection
    • Time frameBetween-groups differences in salivary cortisol of healthy volunteers with different sex8:00, 16:00 and 23:00 on the day of sample collection → 8:00 on the day of sample collection
    • Time frameBetween-groups differences in salivary cortisol of healthy volunteers with different body mass index ranges8:00, 16:00 and 23:00 on the day of sample collection → 8:00 on the day of sample collection
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07168122
Lead sponsor
Shanghai 6th People's Hospital
Responsible party
Jian Zhou (Principal Investigator, Professor, Chief Physician, Deputy Director, Shanghai 6th People's Hospital) — Principal investigator
First posted
Sep 11, 2025
Start date
Jan 1, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Jian Zhou, Doctor
Contact
zhoujian@sjtu.edu.cn
+86-021-64369181

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion